Dr. Lyn Guenther
Dr. Lyn Guenther is a Professor of dermatology at Western University in London Ontario Canada, Fellow of the College of Physicians and Surgeons of Canada (FRCPC) and is Board-Certified in the United States. She received her MD degree from the University of Western Ontario and completed her dermatology residency training at the University of Michigan, Ann Arbor Michigan, USA. She has been involved in more than 160 research projects since 1980 and is the president of Guenther Research Inc.
Dr. Guenther was the President of the Canadian Society for Dermatologic Surgery from 2001 to 2003. She chaired the Canadian expert panel for the treatment of moderate-to-severe psoriasis in 2004, was a member of the expert panel for the 2009 and 2016 Canadian Psoriasis Guidelines. She was also a member of the 2015 Canadian Non-melanoma Skin Cancer Guidelines Committee.
Dr. Guenther has more than 200 publications, is a reviewer for a number of journals, and has been the medical editor of Dermatology Times of Canada since 1998. She has lectured to medical students at St. George’s University in Grenada and has acted as an advisor to Health Canada, the Drug Quality and Therapeutics Committee for Ontario, the Canadian Medical Protective Association, the Canadian Cancer Society, and many pharmaceutical companies.
Dr. Guenther enjoys teaching and lectures locally, provincially, nationally and internationally. She has won a certificate of appreciation for excellence in undergraduate medical education and since 2007, has been voted “Best Doctor” by peers.
Thursday NOV 11, 2021
Optimal use of Topical Treatment in AD – Tips for Clinical Practice Using Crisaborole
This open session aims to:
- Review best clinical practices in topically treating AD patients
- Explore optimal use of crisaborole in mild to moderate AD
- Provide expert guidance for the real-world use of crisaborole ointment to improve patients’ outcomes
Atopic dermatitis (AD) is a lifelong inflammatory skin condition associated with altered immune function and epidermal barrier dysfunction. Mild to moderate disease is usually controlled by behavioral measures such as skin care and avoidance of triggers and treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).
Evidence from the literature coupled with the panels' expert opinion, experiences and, key insights have given rise to the recommendations on optimal crisaborole ointment use for patients with mild-to-moderate AD. The ointment provides a good and safe alternative to TCS and TCI.
The presentation discusses best clinical practices in the topical treatment of mild to moderate AD patients and provides expert guidance for the real-world use of crisaborole ointment.
Atopic dermatitis is a chronic condition in which patients may oscillate between degrees of severity over time and may have different levels of severity in various skin areas at any one time. Therefore, the best treatment paradigms reflect a need for a range of products that target these different levels of severity.
Crisaborole is a nonsteroidal PDE4-I with demonstrated efficacy in patients aged three months and older with mild to moderate AD. It is a well-tolerated alternative to TCS or TCI and can be used on any body site. It may be especially beneficial for areas with thicker skin, such as hands and feet. There are no concerning safety signals associated with crisaborole; other than its possible burning sensation. Information and education on measures to avoid side effect can help optimize results and adherence.
Cases will be presented to illustrate best clinical practices in the topical treatment of mild to moderate AD patients with crisaborole.